Prostate cancer risk-associated variants have been reported in populations of European descent, African-Americans and Japanese using genome-wide association studies (GWAS).
To systematically investigate prostate cancer risk-associated variants in Chinese men, we performed the first GWAS in Han Chinese. In addition to confirming several associations reported in other ancestry groups, this study identified two new riskassociated loci for prostate cancer on chromosomes 9q31.2 (rs817826, P = 5.45 × 10 −14 ) and 19q13.4 (rs103294, P = 5.34 × 10 −16 ) in 4,484 prostate cancer cases and 8,934 controls. The rs103294 marker at 19q13.4 is in strong linkage equilibrium with a 6.7-kb germline deletion that removes the first six of seven exons in LILRA3, a gene regulating inflammatory response, and was significantly associated with the mRNA expression of LILRA3 in T cells (P < 1 × 10 −4 ). These findings may advance the understanding of genetic susceptibility to prostate cancer.
Prostate cancer is the second most frequently diagnosed cancer and the sixth leading cause of cancer-related death in men, with an estimated 914,000 new cases and 258,000 deaths per year globally 1 . Incidence and mortality rates for prostate cancer vary by 25-fold and 10-fold, respectively, around the world 1 . The highest incidence rates are found in Western developed countries, and the highest mortality rates are found in African-Americans, whereas the lowest incidence and mortality rates are reported in Asians. These differences suggest genetic heterogeneity as well as different environmental exposures in prostate cancer development in various ancestry groups.
Multiple GWAS of prostate cancer have been performed in populations of European descent, and more than 40 prostate cancer susceptibility loci have been identified [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . In addition, GWAS of prostate cancer in Japanese 13, 14 and African-American 15 populations identified eight and one novel loci for prostate cancer, risk, respectively. However, no GWAS for prostate cancer has been reported in the Chinese population.
In this study, we performed a multistage GWAS of prostate cancer in the Chinese Consortium for Prostate Cancer Genetics (ChinaPCa), with a total of 4,484 prostate cancer cases and 8,934 controls from Han Chinese population. The characteristics of the subjects in each stage are summarized in Supplementary Table 1. In the first stage, 731,458 SNPs were genotyped in 1,497 cases and 1,008 controls using Illumina Human OmniExpress BeadChips. After quality control filtering (Online Methods), 587,294 SNPs in 1,417 cases and 1,008 controls were retained in the subsequent analyses. A principal-component analysis was first performed using EIGENSOFT software 16 to assess the genetic background of the subjects. Results from this analysis were consistent with subjects being Han Chinese ( Supplementary  Fig. 1 ). The distribution of the top two eigens is shown in Supplementary Figure 2 . We performed association analysis for each of these SNPs with prostate cancer risk with PLINK 17 , assuming an additive model and adjusting for the first eigen. Quantile-quantile plot analysis of the association results showed an inflation factor (λ) of 1.08 (Supplementary Fig. 3 ). Similar results were found when analysis was adjusted for the top two eigens (λ = 1.08), likely reflecting differences in the ascertainment of cases and controls (Online Methods). Across the genome, one SNP at 8q24 (rs1456315, P = 1.18 × 10 −12 ) exceeded the predefined genome-wide significance level of P < 5.0 × 10 −8 ( Supplementary Fig. 4 ). This SNP is located in region 2 of 8q24, which has previously been reported as a prostate cancer Genome-wide association study in Chinese men identifies two new prostate cancer risk loci at 9q31.2 and 19q13.4 l e t t e r s susceptibility locus 3 Table 2 ). Suggestive evidence for association was also found for many other regions throughout the genome, although these associations did not reach genome-wide significance. These regions include eight additional prostate cancer risk-associated loci previously reported in populations of European descent and four loci reported in the Japanese population (P < 0.05) (Supplementary Table 2 ).
(Supplementary
To confirm new prostate cancer risk-associated loci suggested in the first stage of the GWAS, we selected a subset of independently associated SNPs for replication on the basis of three criteria: (i) P < 5.0 × 10 −3 in the association test (4,323 SNPs met this criterion), (ii) r 2 < 0.5 for linkage disequilibrium (LD) between SNPs (166 SNPs met both of these criteria) and (iii) similar allele frequency in the controls to that reported in two additional large GWAS of Chinese populations (difference of ≤0.02) 18, 19 (43 SNPs met all three criteria) (Online Methods). Forty-three independent SNPs were selected and genotyped in an additional 782 cases and 1,792 controls (replication 1). Association analysis using the same method as in the GWAS stage confirmed two SNPs that associated at P < 1.16 × 10 −3 (accounting for 43 independent tests): rs817826 at 9q31.2 (P = 1.05 × 10 −3 ) and rs103294 at 19q13.4 (P = 4.98 × 10 −7 ) (Supplementary Table 3 ). To further confirm these associations, we genotyped these two SNPs in two additional case-control series (replication 2: 1,102 cases and 4,501 controls; replication 3: 1,183 cases and 1,633 controls). These two SNPs showed significant association in each stage (replication 2: rs817826, P = 3.09 × 10 −7 and rs103294, P = 2.62 × 10 −3 ; Results in an additive model from GWAS and replication stages were combined by meta-analysis using a fixed-effect model under the absence of heterogeneity among studies for both loci (rs817826: P = 0.83, I 2 = 0; rs103294: P = 0.53, I 2 = 0). npg l e t t e r s replication 3: rs817826, P = 2.22 × 10 −3 and rs103294, P = 3.65 × 10 −4 ) ( Table 1) . After combining the results from all four stages using a meta-analysis assuming a fixed effect, associations at these two SNPs exceeded genome-wide significance. For rs817826 at 9q31.2, the rs817826[C] allele was associated with an odds ratio (OR) of 1.41 for prostate cancer risk (95% confidence interval (CI) = 1.29-1.54; P = 5.45 × 10 −14 ). For rs103294 at 19q13.4, the rs103294[C] allele was associated with an OR of 1.28 for prostate cancer risk (95% CI = 1.21-1.36; P = 5.34 × 10 −16 ). There was no evidence for heterogeneity among the four stages at rs817826 (P het = 0.83, I 2 = 0) or rs103294 (P het = 0.53, I 2 = 0). To further characterize prostate cancer associations at these two loci, we imputed known common SNPs in the flanking regions of these SNPs for subjects in the first-stage GWAS on the basis of haplotype data from the 1000 Genomes Project Han Chinese in Beijing, China (CHB) and Japanese in Tokyo, Japan (JPT) subjects (Phase 1 integrated data version 3, released March 2012) using IMPUTE2.2.2 software (Fig. 1) . Flanking regions were determined for each locus on the basis of local LD information (r 2 ≥ 0.10) and association results (P < 0.01) from the first-stage data (~17.5 kb for 9q31.2 and ~48 kb for 19q13.4). Considering that only a small number of SNPs were successfully imputed in the region of 19q13.4, we genotyped an additional 19 SNPs in this region (Online Methods). None of the additional SNPs in either of these regions showed a stronger association with prostate cancer than the respective index SNP (rs817826 and rs103294). After conditioning on the index SNP at each region, no association was found at P < 0.01 for the remaining SNPs at 9q31. 2 Tables 4 and 5) , suggesting that no additional independent prostate cancer risk-associated loci exist in these two regions.
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We also examined associations of these two SNPs with clinical characteristics of prostate cancer in a case-only analysis (Supplementary Table 6 ). No significant associations were observed with prostate-specific antigen (PSA) levels at diagnosis, Gleason score, tumor, node, metastasis (TNM) stage or aggressiveness in the combined prostate cancer cases from the four stages. Similarly, we did not find any association of these two SNPs with serum PSA levels in the controls (Supplementary Fig. 5) .
We tested association of these two SNPs with prostate cancer risk in two populations of European descent: Cancer Genetic Markers of Susceptibility (CGEMS) in the United States and CAncer Prostate in Sweden (CAPS) (Supplementary Table 7) . For rs103294 at 19q13.4, the allele frequency differed considerably in the population of European descent from that seen in the Chinese population, and no association was found. For rs817826 at 9q31, however, the allele frequency was similar to that seen in the Chinese population, the reported risk allele showed higher frequency in cases relative to controls in both studies and the association with prostate cancer risk was statistically significant in the combined analysis of these two studies (P = 0.023). Further studies in other ancestry groups are warranted, including evaluation of the broader regions surrounding each implicated prostate cancer risk-associated SNP.
We next performed expression quantitative trait locus (eQTL) analysis to examine whether the two prostate cancer risk-associated SNPs correlate with expression of nearby genes within a 2-Mb region centered on the index SNP, using a publicly available database 20 (Online Methods and Supplementary Table 8 ). The rs103294[C] risk allele at 19q13.4 was consistently associated with increased expression of LILRA3 (encoding leukocyte immunoglobulin-like receptor subfamily A member 3) in T cells from 75 individuals, as measured by 2 probes for the gene (P ≤ 1 × 10 −4 after permutation) 21 (Supplementary Fig. 6 ). No consistent association with expression was found in other cell types and tissues for LILRA3 and other surrounding genes. No correlation was observed between rs817826 at 9q31.2 and expression of nearby genes in any measured cell type (fibroblast, lymphoblastoid cell line and T cell) 21 or tissue type (adipose, lymphoblastoid cell line and skin) 22 Table 8 ). Considering the small number of samples used in eQTL analysis, additional studies are needed to better understand the association of these SNPs with the mRNA expression of nearby genes.
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The rs103294 SNP is located within the leukocyte immunoglobulinlike receptor (LIR) gene cluster at 19q13.4. The LD block containing rs103294 overlaps with LILRA3 (Fig. 1) . There is a 6.7-kb known germline deletion within the LILRA3 gene that removes the first six of a total of seven exons in the gene 23 (Fig. 2) . The deletion was reported to be more common in Northeastern Asians (0.56-0.84) than Europeans (0.17) or individuals from other populations (0.10-0.26) 24 . We measured the deletion status in all the subjects in the GWAS stage using a previously reported method 24 . Strong LD between the deletion variant and rs103294 (r 2 = 0.83) was observed, and the nondeleted allele was on the haplotype containing the rs103294[C] risk Deletion   rs6509859  rs595872  rs402071  rs17273295  rs7254645  rs444004  rs4022330  rs3848607  rs8100863  rs397600  rs6509860  rs798887  rs117311656   rs427366  rs17305346  rs103294  rs368178  rs410852  Deletion  rs453755 npg l e t t e r s allele (Fig. 2) . The non-deleted allele was more common in cases (0.307) than controls (0.252) (P = 9.60 × 10 −4 ; Supplementary The rs817826 SNP at 9q31.2 resides in an intergenic region between RAD23B (62 kb centromeric) and KLF4 (91 kb telomeric), and the LD block containing rs817826 does not overlap with these two genes (Fig. 1) . A bioinformatics analysis at this region, based on Encyclopedia of DNA Elements (ENCODE) data annotated by the UCSC browser, did not reveal additional functional regions (Supplementary Fig. 7 ). Additional genetic and functional studies are needed to delineate the mechanism by which the 9q31.2 locus contributes to prostate cancer development.
In summary, we conducted the first GWAS of prostate cancer in Han Chinese and identified two new susceptibility loci at 9q31.2 and 19q13.4. These findings may improve the understanding of prostate cancer susceptibility and provide clues for further functional studies. Our study highlights the importance of GWAS of complex diseases in diverse populations.
URLs. EIGENSOFT, http://genepath.med.harvard.edu/~reich/ Software.htm; Genevar, http://www.sanger.ac.uk/resources/software/ genevar; HapMap, http://hapmap.ncbi.nlm.nih.gov/; IMPUTE, https://mathgen.stats.ox.ac.uk/impute/impute.html; LocusZoom, http://csg.sph.umich.edu/locuszoom/; PLINK 1.07, http://pngu.mgh. harvard.edu/~purcell/plink/download.shtml; R statistical software, http://www.r-project.org/; UCSC database, http://genome.ucsc.edu/.
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